Invesco Ltd. Has $1.63 Million Position in InMode Ltd. (NASDAQ:INMD)

Invesco Ltd. boosted its holdings in shares of InMode Ltd. (NASDAQ:INMD) by 1.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 97,475 shares of the healthcare company’s stock after purchasing an additional 1,444 shares during the quarter. Invesco Ltd. owned about 0.14% of InMode worth $1,628,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new stake in shares of InMode in the fourth quarter worth $87,000. Farther Finance Advisors LLC raised its position in shares of InMode by 26.2% during the fourth quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company’s stock valued at $93,000 after buying an additional 1,154 shares during the last quarter. Pilgrim Partners Asia Pte Ltd bought a new stake in shares of InMode in the fourth quarter valued at about $114,000. WINTON GROUP Ltd acquired a new stake in InMode during the fourth quarter worth about $174,000. Finally, HighTower Advisors LLC bought a new position in InMode during the fourth quarter valued at about $180,000. Institutional investors and hedge funds own 68.04% of the company’s stock.

Analyst Upgrades and Downgrades

INMD has been the topic of several recent research reports. Canaccord Genuity Group decreased their price objective on InMode from $17.00 to $15.00 and set a “hold” rating on the stock in a report on Tuesday. BTIG Research lowered shares of InMode from a “buy” rating to a “neutral” rating in a report on Tuesday. Barclays raised their price objective on shares of InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 5th. UBS Group dropped their price target on shares of InMode from $19.00 to $16.25 and set a “neutral” rating for the company in a research report on Tuesday. Finally, Baird R W downgraded InMode from a “strong-buy” rating to a “hold” rating in a report on Monday. Seven research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $19.38.

InMode Trading Up 1.1 %

NASDAQ INMD opened at $14.42 on Wednesday. InMode Ltd. has a 1-year low of $13.68 and a 1-year high of $19.85. The company has a 50 day moving average of $17.16 and a 200-day moving average of $17.61. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of 6.14 and a beta of 1.96.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.